Form D · Biotechnology

Odyssey Therapeutics, Inc.

Boston, MA · CIK 0001882782

Offering snapshot reported Dec 4, 2025 · SEC filing

Reported sold
$214M
Offering amount: $214M
Investors reported
55
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jun 16, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Dec 4, 2025Initial$214,025,200No comparison55SEC filing
Aug 14, 2024Amendment$117,210,000$20,080,000vs Dec 15, 202343SEC filing
Dec 15, 2023Initial$97,130,000No comparison39SEC filing
Oct 27, 2022Initial$168,009,933No comparison34SEC filing
Oct 14, 2021Initial$91,629,837No comparison63SEC filing

Offering details

Securities
Equity, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-565797

Source: Form D, filed Dec 4, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Charles M. Baum Director
M. Charles Baum Director
Chuck Baum Director
Jill Carroll Director
Shelley Chu Director
Gary D. Glick Director, Executive
Carl Gordon Director
Jason Haas Executive
Paulina Hill Director
Lorence Kim Director
Jeffrey Leiden Director
Nan Li Director
Carolyn Ng Director
Valerie Odegard Director
Ksenija Pavletic Director
Lan F. Smith Director
Ian Smith Director
Nia Tatsis Director
Timothy Walbert Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
51 Sleeper Street
Boston, MA, 02210